Argenx
ARGX
#416
Rank
ยฃ42.08 B
Marketcap
ยฃ675.73
Share price
-0.05%
Change (1 day)
41.00%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Revenue for Argenx (ARGX)

Revenue in 2025 (TTM): ยฃ2.72 Billion

According to Argenx 's latest financial reports the company's current revenue (TTM ) is ยฃ2.70 Billion. In 2024 the company made a revenue of ยฃ1.74 Billion an increase over the revenue in the year 2023 that were of ยฃ0.96 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Argenx from 2013 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) ยฃ2.72 B56.36%
2024 ยฃ1.74 B81.32%
2023 ยฃ0.96 B183.51%
2022 ยฃ0.33 B
2019 ยฃ66.77 M191.1%
2018 ยฃ22.93 M-38.25%
2017 ยฃ37.14 M168.13%
2016 ยฃ13.85 M148.44%
2015 ยฃ5.57 M50.43%
2014 ยฃ3.7 M23.31%
2013 ยฃ3 M